Protagenic Therapeutics Inc Sustainability Reports
Protagenic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of peptide-based therapeutics for the treatment of stress-related neuropsychiatric and mood disorders. Its primary drug candidate is PT00114, a synthetic brain signaling peptide designed to mitigate overactive stress responses.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300KPBYAVJLPDKB70
FIGI: BBG001S5T780
5 reports from 2016 to 2024
